GlassScriptPhysician profile
Kurtis M Holmes
NPI 1750464632
$55,985.56
in general payments reported to CMS, 2019-2025
28 companies · $83.60 in 2025
The $83.60 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $14K · 2021: $13K · 2022: $6,415 · 2023: $7,624 · 2024: $165 · 2025: $83.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,180 · Food and Beverage: $693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,180.00 |
| Food and Beverage | $692.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $47,140.00 | 2019-2022 | |
| Csl Plasma INC. | $7,180.00 | 2023 | |
| Abbvie INC. | $251.23 | 2021-2025 | |
| Glaxosmithkline, LLC. | $208.25 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $206.33 | 2019-2024 | Breztri, Airsupra |
| Astellas Pharma US INC | $117.26 | 2022-2025 | Veozah |
| Pfizer INC. | $115.60 | 2019-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $112.48 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $96.85 | 2021 | |
| Janssen Pharmaceuticals, INC | $90.25 | 2020-2024 | Spravato |
| Amgen INC. | $83.08 | 2019-2025 | Evenity, Prolia, Prolia |
| Lilly USA, LLC | $57.45 | 2022-2023 | Mounjaro |
| Novo Nordisk INC | $42.08 | 2019-2021 | |
| Allergan, INC. | $31.07 | 2020 | |
| Brainsway USA INC | $27.45 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $24.32 | 2022 | |
| Neurelis, INC. | $23.87 | 2021 | |
| Dexcom, INC. | $23.74 | 2023 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $22.99 | 2021 | |
| Edwards Lifesciences Corporation | $19.46 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Nestle Healthcare Nutrition INC. | $16.91 | 2021 | |
| Seqirus USA INC | $15.10 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.25 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $14.10 | 2024 | Bd Onclarity |
| Avanir Pharmaceuticals, INC. | $13.64 | 2022 | |
| Radius Health, INC. | $13.22 | 2020 | |
| Pacira Therapeutics, INC. | $13.21 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kurtis Holmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.